Upgrade to SI Premium - Free Trial

Mizuho Reiterates Outperform Rating on Relmada Therapeutics Inc (RLMD)

April 8, 2026 6:39 AM
Mizuho analyst Uy Ear reiterated an Outperform rating and $19.00 price target on Relmada Therapeutics Inc (NASDAQ: RLMD).The analyst commented ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Categories

Analyst Comments